A PYMNTS Company

US: Takeda loses bid to DQ Baker Botts in antitrust case

By  |  June 9, 2019

Takeda Pharmaceutical Company on Thursday, June 6, lost a bid to disqualify Baker Botts from representing generic drug company Zydus Pharmaceuticals in a lawsuit accusing Takeda of an antitrust violation.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Affirming a magistrate judge, US District Judge Freda Wolfson in Trenton, New Jersey, rejected Takeda’s argument that it had an implied attorney-client relationship with Baker Botts because of the firm’s previous representation of Takeda’s co-plaintiff in related patent litigation.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.